Protein profile at newly restored implants compared to contralateral teeth over 12-months: a pilot study
Clinical Oral Investigations · 2024
DOI: 10.1007/s00784-024-05984-w ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Clinical Oral Investigations, 2024. Verfasst von Danae A Apatzidou und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Preventive Dentistry, Periodontology and Implant Biology, Faculty of Dentistry, Aristotle University of Thessaloniki, Thessaloniki, Gre…. Hauptthemen laut MEDLINE: Dental Implants, Gingival Crevicular Fluid, Proteomics. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 66 Literaturangaben.
Abstract (Originalsprache)
OBJECTIVES: To determine crevicular fluid alterations in protein expression of newly restored implants during their first year of function and associate them with those of contralateral teeth. MATERIALS AND METHODS: In ten non-smokers, successfully treated for periodontitis, one newly restored implant (baseline-T0) and one corresponding tooth were followed for 12-months (T1). Oral hygiene was monitored during the study. Periodontal clinical indices and crevicular fluid were collected from an implant-site (PICF) and a tooth-site (GCF). Total proteomic profiles of PICF and GCF were investigated using label-free quantitative proteomics. RESULTS: Clinical recordings remained stable at 12-months on the tooth-/implant-site basis. The comparative analysis of protein enrichment between teeth and implants at T0 revealed 664 human proteins, with 93 found only in teeth and 217 exclusively in implants. Among the 354 overlapping proteins, 46 were upregulated (log2FC > 1) in teeth, while 61 in implants. At T1, 569 human proteins were exclusively identified, with 67 found only in teeth and 193 exclusively in implants. Of the 309 overlapping proteins, 22 were upregulated in teeth, while 48 were in implants. The over-representation enrichment analysis identified "interferon-alpha response" and "allograft rejection" pathways, as significantly regulated categories at T0, with the latter being over-represented at T1. CONCLUSIONS: Peri-implant tissue maturation was evident during the study. Proteins expressed in crevicular fluid reflected unique patterns between implants and teeth that are worth studying. CLINICAL RELEVANCE: Different proteomic patterns were observed at the implant-site compared to the contralateral tooth-site towards inflammatory processes that prevail within otherwise clinically healthy peri-implant tissues. CLINICAL TRIAL REGISTRATION NUMBER: ClinicalTrials.gov ID: NCT06379022.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Preventive Dentistry, Periodontology and Implant Biology, Faculty of Dentistry, Aristotle University of Thessaloniki, Thessaloniki, Greece. perioapatzidou@yahoo.gr.
- Department of Preventive Dentistry, Periodontology and Implant Biology, Faculty of Dentistry, Aristotle University of Thessaloniki, Thessaloniki, Greece.
- Division of Oral Health and Periodontology, Department of Dental Medicine, Karolinska Institutet, Stockholm, Sweden.
Zitieren
APA
Apatzidou, D. A., Violesti, A., Konstantinidis, A., Bao, K., Silbereisen, A., & Bostanci, N. (2024). Protein profile at newly restored implants compared to contralateral teeth over 12-months: a pilot study. Clinical Oral Investigations. https://doi.org/10.1007/s00784-024-05984-w
Vancouver
Apatzidou DA, Violesti A, Konstantinidis A, Bao K, Silbereisen A, Bostanci N. Protein profile at newly restored implants compared to contralateral teeth over 12-months: a pilot study. Clinical Oral Investigations. 2024. doi:10.1007/s00784-024-05984-w
BibTeX
@article{Apatzidou2024,
author = {Apatzidou, Danae A and Violesti, Anastasia and Konstantinidis, Antonis and Bao, Kai and Silbereisen, Angelika and Bostanci, Nagihan},
title = {Protein profile at newly restored implants compared to contralateral teeth over 12-months: a pilot study},
journal = {Clinical Oral Investigations},
year = {2024},
doi = {10.1007/s00784-024-05984-w}
}
EUVIMED